NeoPharm CO., LTD.

KOSDAQ:A092730 株式レポート

時価総額:₩226.0b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

NeoPharm 将来の成長

Future 基準チェック /26

NeoPharm利益と収益がそれぞれ年間18.3%と17.4%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に16% 16.9%なると予測されています。

主要情報

18.3%

収益成長率

16.9%

EPS成長率

Personal Products 収益成長34.0%
収益成長率17.4%
将来の株主資本利益率16.0%
アナリストカバレッジ

Low

最終更新日22 Apr 2024

今後の成長に関する最新情報

Recent updates

NeoPharm CO., LTD. (KOSDAQ:092730) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected

Jun 13
NeoPharm CO., LTD. (KOSDAQ:092730) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected

Benign Growth For NeoPharm CO., LTD. (KOSDAQ:092730) Underpins Its Share Price

Apr 24
Benign Growth For NeoPharm CO., LTD. (KOSDAQ:092730) Underpins Its Share Price

NeoPharm's (KOSDAQ:092730) Earnings Are Weaker Than They Seem

Mar 25
NeoPharm's (KOSDAQ:092730) Earnings Are Weaker Than They Seem

Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?

Mar 28
Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?

What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?

Mar 15
What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?

How Much Did NeoPharm's(KOSDAQ:092730) Shareholders Earn From Share Price Movements Over The Last Three Years?

Mar 02
How Much Did NeoPharm's(KOSDAQ:092730) Shareholders Earn From Share Price Movements Over The Last Three Years?

We're Watching These Trends At NeoPharm (KOSDAQ:092730)

Feb 18
We're Watching These Trends At NeoPharm (KOSDAQ:092730)

We're Not So Sure You Should Rely on NeoPharm's (KOSDAQ:092730) Statutory Earnings

Feb 08
We're Not So Sure You Should Rely on NeoPharm's (KOSDAQ:092730) Statutory Earnings

NeoPharm CO., LTD. (KOSDAQ:092730) Has Got What It Takes To Be An Attractive Dividend Stock

Jan 26
NeoPharm CO., LTD. (KOSDAQ:092730) Has Got What It Takes To Be An Attractive Dividend Stock

An Intrinsic Calculation For NeoPharm CO., LTD. (KOSDAQ:092730) Suggests It's 31% Undervalued

Jan 15
An Intrinsic Calculation For NeoPharm CO., LTD. (KOSDAQ:092730) Suggests It's 31% Undervalued

Will Weakness in NeoPharm CO., LTD.'s (KOSDAQ:092730) Stock Prove Temporary Given Strong Fundamentals?

Jan 04
Will Weakness in NeoPharm CO., LTD.'s (KOSDAQ:092730) Stock Prove Temporary Given Strong Fundamentals?

NeoPharm CO., LTD. (KOSDAQ:092730) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

Dec 24
NeoPharm CO., LTD. (KOSDAQ:092730) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?

Dec 15
What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?

Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?

Dec 04
Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?

Would Shareholders Who Purchased NeoPharm's (KOSDAQ:092730) Stock Year Be Happy With The Share price Today?

Nov 23
Would Shareholders Who Purchased NeoPharm's (KOSDAQ:092730) Stock Year Be Happy With The Share price Today?

業績と収益の成長予測

KOSDAQ:A092730 - アナリストの将来予測と過去の財務データ ( )KRW Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/2026165,00035,60035,70035,7001
12/31/2025145,00030,10029,70029,7001
12/31/2024120,00023,00023,00023,0001
3/31/2024101,73522,516-1,80820,105N/A
12/31/202397,10523,2132,43523,263N/A
9/30/202392,27120,73322,96724,024N/A
6/30/202389,29219,78120,19921,423N/A
3/31/202386,27218,91218,96619,685N/A
12/31/202285,03317,02717,35418,161N/A
9/30/202286,80518,24517,37318,071N/A
6/30/202287,42417,37017,80918,258N/A
3/31/202287,32116,90518,77519,267N/A
12/31/202187,93117,71321,20321,681N/A
9/30/202186,80218,20720,32020,881N/A
6/30/202185,27518,05921,19021,766N/A
3/31/202185,28718,47418,83719,464N/A
12/31/202081,62518,13116,34317,074N/A
9/30/202081,41318,73411,30917,364N/A
6/30/202082,61819,93512,02818,544N/A
3/31/202082,68019,90116,90924,255N/A
12/31/201983,24019,24512,03019,224N/A
9/30/201979,61118,00215,24517,190N/A
6/30/201974,86316,67513,48815,234N/A
3/31/201969,50015,79510,16812,149N/A
12/31/201866,27515,37014,09616,179N/A
9/30/201863,14313,68211,35113,893N/A
6/30/201860,23613,10512,24414,629N/A
3/31/201857,17512,51411,53712,814N/A
12/31/201753,63411,559N/A10,646N/A
9/30/201749,7659,814N/A10,212N/A
6/30/201746,7399,365N/A9,866N/A
3/31/201743,1648,096N/A9,548N/A
12/31/201642,3697,742N/A9,157N/A
9/30/201643,0975,955N/A8,664N/A
6/30/201641,9995,419N/A6,471N/A
12/31/201535,9653,407N/A6,095N/A
9/30/201319,3501,475N/A2,078N/A

アナリストによる今後の成長予測

収入対貯蓄率: A092730の予測収益成長率 (年間18.3% ) は 貯蓄率 ( 2.5% ) を上回っています。

収益対市場: A092730の収益 ( 18.3% ) KR市場 ( 29.1% ) よりも低い成長が予測されています。

高成長収益: A092730の収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: A092730の収益 ( 17.4% ) KR市場 ( 10.4% ) よりも速いペースで成長すると予測されています。

高い収益成長: A092730の収益 ( 17.4% ) 20%よりも低い成長が予測されています。


一株当たり利益成長率予想


将来の株主資本利益率

将来のROE: A092730の 自己資本利益率 は、3年後には低くなると予測されています ( 16 %)。


成長企業の発掘